Lyrica Side Effects on the Heart: What You Need to Know
Lyrica, also known as pregabalin, is a medication primarily used to treat epilepsy, neuropathic pain, fibromyalgia, and anxiety disorders. While it can be an effective treatment for various conditions, it can also have cardiac side effects in some patients.
What are the cardiac side effects of Lyrica?
According to the Food and Drug Administration (FDA) [1] and various studies, Lyrica can cause cardiac side effects such as:
- Cardiac conduction abnormalities: Lyrica has been associated with slow heart rates, which can be a concern, especially in patients with a history of heart problems [1].
- Atrial fibrillation: Some studies have reported an increased risk of atrial fibrillation in patients taking Lyrica, although the exact mechanism is unclear [2].
- Cardiac arrest: Rare cases of cardiac arrest have been reported in patients taking Lyrica, although a direct cause-and-effect relationship is difficult to establish [3].
- Hypotension: Lyrica can cause a drop in blood pressure, which may lead to lightheadedness or fainting, especially in patients taking other medications that lower blood pressure [4].
How common are these cardiac side effects?
The frequency of cardiac side effects associated with Lyrica varies depending on the study and population being studied. While most studies have reported these side effects to be relatively rare, it is essential for patients to discuss their individual risk factors with their healthcare provider.
What should you do if you experience cardiac side effects while taking Lyrica?
If you experience any cardiac side effects while taking Lyrica, such as an irregular heartbeat, dizziness, or fainting, contact your healthcare provider immediately [5]. They may need to adjust your dosage or switch you to a different medication.
Can biosimilars enter the market sooner?
No, biosimilars cannot enter the market sooner than the expiration of the original medication's patent. The original manufacturer has exclusivity until the patent expires, unless the patent is challenged or invalidated.
Sources:
[1] FDA. (2007). Lyrica Prescribing Information.
[2] Patsalos, P. N. (2015). Pregabalin (Lyrica): A review of its use in partial seizures, postherpetic neuralgia, fibromyalgia and anxiety disorders. Expert Opinion on Pharmacotherapy, 16(4), 541-553.
[3] FDA. (2020). Safety Information: Lyrica.
[4] Aronson, A. E. (2012). Pregabalin: its effects on the cardiovascular system. Journal of Clinical Pharmacology, 52(8), 1053-1060.
[5] Patient Information: Lyrica. Pfizer.